Dexmedetomidine in Patients After Intracranial Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

192 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-10-31

Study Completion Date

2013-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Dexmedetomidine is a highly selective a2-adrenoreceptor agonist that produces dose-dependent sedation and analgesia without respiratory depression. Dexmedetomidine has been used in critically ill medical, surgical, and pediatric patients. No study has been designed specifically to evaluate dexmedetomidine uses in the neurocritical care population. The primary objective is to evaluate the safety and efficacy of dexmedetomidine for prophylactic analgesia and sedation in patients after intracranial surgery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Impact Dexmedetomidine on Postoperative Delirium in Patients After Intracranial Operation for Brain Tumor

NCT04494828

Central Nervous System Diseases

COMPLETED PHASE4

Dexmedetomidine for Prevention of Postoperative Delirium After Intracranial Operation for Brain Tumor

NCT04399343

Central Nervous System Diseases

UNKNOWN PHASE4

Small-dose Dexmedetomidine Effects on Recovery Profiles of Supratentorial Tumors Patients From General Anesthesia

NCT02007798

Brain Neoplasms Surgery

UNKNOWN NA

Effect of Dexmedetomidine on Central Nervous System Complications in Patients Undergoing Cardiac Surgery

NCT06551259

Randomized Controlled Trial Dexmedetomidine

COMPLETED PHASE4

Dexmedetomidine Improves Recovery After Cranial Aneurysm Surgery

NCT03355534

Aneurysm Cerebral

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The PASTrial is a non-commercial, multi-center, randomized, placebo-controlled, double blinded clinical trial. The study compares dexmedetomidine versus normal saline (placebo) in patients after intracranial surgery with delayed extubation. In dexmedetomidine group, infusion (0.4μg/kg/h) is started when patients are admitted to neuro-intensive care unit for postoperative recovery. In control group, patients receive normal saline infusion at the same rate and volume in dexmedetomidine group. The patient's level of sedation is assessed by Sedation-Agitation Scale (SAS) per hour. Midazolam is administered in 0.3-0.5 mg bolus or continuous infusion as SAS above 4. The study is designed primarily to compare the percentage of patients with agitation and requiring midazolam infusion in the 2 study arms.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Central Nervous System Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dexmedetomidine group

Group Type EXPERIMENTAL

Dexmedetomidine

Intervention Type DRUG

Intravenous infusion at rate of 0.4μg/kg/h, during the first 24 hours postoperatively

Placebo group

Group Type PLACEBO_COMPARATOR

Normal saline

Intervention Type DRUG

as placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.